We are live on ! Find out more
TVRD

Tvardi Therapeutics
TVRD

73 hedge funds and large institutions have $102M invested in Tvardi Therapeutics in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,253% more call options, than puts

Call options by funds: $1.72M | Put options by funds: $73K

283% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 6

283% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 6

128% more capital invested

Capital invested by funds: $44.9M → $102M (+$57.3M)

30% more funds holding

Funds holding: 56 → 73 (+17)

7.23% more ownership

Funds ownership: 20.78% → 28% (+7.2%)

Holders
73
Holders Change
+17
Holders Change %
+30.36%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
23
Reduced
6
Closed
6
Calls
$1.72M
Puts
$73K
Net Calls
+$1.65M
Net Calls Change
+$1.65M

Top Buyers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
+$4.75M
2
Invesco
Invesco
Georgia
+$2.35M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.34M
4
PHP
Parkman Healthcare Partners
Connecticut
+$1.85M
5
BlackRock
BlackRock
New York
+$1.77M

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$583K
2
HT
Headlands Technologies
Illinois
-$80K
3
Bank of America
Bank of America
North Carolina
-$49.1K
4
Morgan Stanley
Morgan Stanley
New York
-$31.5K
5
Citigroup
Citigroup
New York
-$30.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
LI
51
LRI Investments
Florida
$3.2K – – –
Citigroup
52
Citigroup
New York
$2.81K -$30.8K -1,080 -94%
PNC Financial Services Group
53
PNC Financial Services Group
Pennsylvania
$1.87K +$1.37K +48 New
Osaic Holdings
54
Osaic Holdings
Arizona
$1.02K -$342 -12 -29%
Jones Financial Companies
55
Jones Financial Companies
Missouri
$908 +$28 +1 +4%
ME
56
McIlrath & Eck
Washington
$779 – – –
AF
57
Allworth Financial
California
$741 – – –
HI
58
Harbour Investments
Wisconsin
$585 +$28 +1 +7%
Group One Trading
59
Group One Trading
Illinois
$546 – – –
LSA
60
Leonteq Securities AG
Switzerland
$468 – – –
MCM
61
MAI Capital Management
Ohio
$390 – – –
CPG
62
Cornerstone Planning Group
New Jersey
$330 +$968 +34 +3,400%
NA
63
NewEdge Advisors
Louisiana
$312 +$228 +8 New
CFD
64
Creative Financial Designs
Indiana
$234 – – –
PPA
65
Painted Porch Advisors
California
$234 – – –
SS
66
SBI Securities
Japan
$156 – – –
TC
67
Truvestments Capital
Florida
$156 – – –
Rockefeller Capital Management
68
Rockefeller Capital Management
New York
$156 +$114 +4 New
FFA
69
Farther Finance Advisors
California
$117 – – –
SIS
70
Sound Income Strategies
Florida
$86 – – –
Comerica Bank
71
Comerica Bank
Texas
$39 – – –
FRA
72
Front Row Advisors
California
$39 – – –
Marshall Wace
73
Marshall Wace
United Kingdom
– -$583K -24,980 Closed
HT
74
Headlands Technologies
Illinois
– -$80K -3,431 Closed
Raymond James Financial
75
Raymond James Financial
Florida
– -$1.52K -65 Closed
1 2
3
4

TVRD Hedge Fund Activity: Q3 2025 in Review

73 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2025, worth a combined $102M — up 128% from $44.9M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new TVRD positions and 6 closed out — a net gain of 17 holders — while 23 added to existing stakes and 6 trimmed.

The largest buyer was Vestal Point Capital, opening a new position worth an estimated $4.75M. The largest seller was Marshall Wace, exiting entirely with an estimated $583K sold.

  • 73 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2025, up from 56 in Q2 2025.
  • Funds reported $102M of Tvardi Therapeutics stock for Q3 2025, up 128% quarter-over-quarter.
  • 23 funds opened new Tvardi Therapeutics positions in Q3 2025 and 6 closed out, a net change of +17 holders.
  • The largest Tvardi Therapeutics buyer in Q3 2025 was Vestal Point Capital, an estimated $4.75M added.
  • The largest Tvardi Therapeutics seller in Q3 2025 was Marshall Wace, an estimated $583K sold.

Based on aggregated 13F filings for Q3 2025.